Lercanidipine capsules
    1.
    发明申请
    Lercanidipine capsules 审中-公开
    Lercanidipine胶囊

    公开(公告)号:US20060073200A1

    公开(公告)日:2006-04-06

    申请号:US11244315

    申请日:2005-10-04

    IPC分类号: A61K31/455 A61K9/48

    摘要: The invention provides a modified release lercanidipine pharmaceutical composition comprising at least one waxy substance and a therapeutically effective amount of lercanidipine, wherein oral administration of the modified release lercanidipine pharmaceutical composition to a patient results in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for the full time period of about 24 hours after administration of the composition to the patient.

    摘要翻译: 本发明提供了包含至少一种蜡质物质和治疗有效量的氯卡地平的改良释放氯卡地平药物组合物,其中向患者口服给予改良释放的氯卡地平药物组合物导致平均lercanidipine血药浓度大于0.5ng / ml 在将组合物施用于患者后约24小时的全部时间段。

    Transmucosal gel formulations
    2.
    发明申请
    Transmucosal gel formulations 审中-公开
    透粘胶凝胶制剂

    公开(公告)号:US20050260253A1

    公开(公告)日:2005-11-24

    申请号:US11134743

    申请日:2005-05-20

    摘要: This invention relates to pharmaceutical formulations for the transmucosal delivery of 4-amino-6,7-dimethoxy-2-{4-[(2-isopropyl-6-methoxyphenoxy)acetyl]-1-piperazinyl}quinazoline (Rec 15/2615), which has the formula: The formulations are useful in methods for enhancing the sexual act for females, including treatment of female sexual dysfunction.

    摘要翻译: 本发明涉及用于经粘膜递送4-氨基-6,7-二甲氧基-2- {4 - [(2-异丙基-6-甲氧基苯氧基)乙酰基] -1-哌嗪基}喹唑啉(Rec 15/2615)的药物制剂, 其具有以下公式:该制剂可用于增强女性性行为的方法,包括治疗女性性功能障碍。